AZN · Astrazeneca PLC
Market Cap
$252.33B
Shares
1.55B
AZN metrics
51 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$162.70
Market cap
$252.33B
Price action
19 metricsPrice change (1W)
+0.0%
Price change (30D)
+0.8%
Price change (3M)
-12.5%
Price change (6M)
-16.2%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
29.4%
Beta
0.1
RSI (14D)
46.4
Price vs SMA 50
-3.8%
Price vs SMA 200
—
Avg volume (3M)
3.11M
Relative volume
1.0
Average dollar volume
$524.69M
Company
3 metricsSector
Healthcare
Industry
Drug Manufacturers - General
Shares outstanding
1.55B
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
4.1×
reciprocal yield 24.3%
P / book
5.0
reciprocal yield 19.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
1.8%
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
$2.95
Dividend growth YoY
-52.9%
Dividend growth streak
2
Last ex-dividend
2026-08-07
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-04-29
Profitability
9 metricsGross margin
81.9%
Operating margin
23.4%
Trailing 12 months
Net margin
17.4%
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+6.4%
Year over year
Net income growth YoY
+2.3%
Revenue (TTM)
$61.37B
Trailing 12 months
EPS growth YoY
+2.5%
Shares change YoY
—
Year over year · more shares
Revenue CAGR (3Y)
+9.8%
Revenue CAGR (5Y)
+17.2%
EPS CAGR (3Y)
+15.7%
EPS CAGR (5Y)
+6.0%
FCF CAGR (3Y)
+10.5%
FCF CAGR (5Y)
+25.1%
Quality
14 metricsReturn on equity
21.0%
Return on assets
9.0%
Debt / equity
—
Current ratio
0.9
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$22.11B
Latest balance sheet
Cash & equivalents
$5.71B
Total assets
$115.83B
Total debt
$27.82B
Cash flow & spend
7 metricsOperating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
1,468
13F filer change QoQ
+134
Institutional ownership
52.3%
Short interest
3 metricsShort interest
0.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
24 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—